Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Urine PD-L1 as a non-invasive biomarker for immune checkpoint inhibitor (ICI) therapy in bladder cancer

Advances in Biomarker Sciences and Technology(2025)10.1016/j.abst.2025.05.001Source: DataRank Database

Urine PD-L1 as a non-invasive biomarker for immune checkpoint inhibitor (ICI) therapy in bladder cancer is a research paper published in Advances in Biomarker Sciences and Technology (2025). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (7 grants)Impact (FWCI 1.03)OA: goldTopics (18)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (9)

Peng Wang ORCID,Shang-Jui Wang ORCID,Akshay Sood,Lingbin Meng ORCID,Cheryl Lee ORCID

Live enrichment

PubMed:42170242 PMC:PMC13188407 OpenAlex:https://openalex.org/W4410529969

NCI NIH HHS

Grant: R01 CA276474

NCI NIH HHS

Grant: R01 CA222148

NCI NIH HHS

Grant: U01 CA278927

NCI NIH HHS

Grant: R33 CA258016

National Institutes of Health

National Institutes of Health National Cancer Institute

Ohio State University

FWCI

1.03

Citation Percentile

0.7%

Citation Trend

2025

goldLicense: cc-by

journalhttps://doi.org/10.1016/j.abst.2025.05.001

publisherhttps://doi.org/10.1016/j.abst.2025.05.001

publisherhttps://api.elsevier.com/content/article/PII:S2543106425000110?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2543106425000110?httpAccept=text/plain

repositoryhttps://pubmed.ncbi.nlm.nih.gov/42170242

Fields of Study

Bladder and Urothelial Cancer TreatmentsUrinary and Genital Oncology StudiesCancer Immunotherapy and Biomarkers

Keywords

Bladder cancerBiomarkerMedicineUrineOncologyCancerImmune checkpointInternal medicineCancer researchImmunotherapyBiologyDiagnostic ToolPrognostic ToolNon-invasive DetectionUpd-L1

Sustainable Development Goals

SDG 0: Zero hunger

Urine PD-L1 as a non-invasive biomarker for immune checkpoint inhibitor (ICI) therapy in bladder cancer

FAIR Checklist

Authors (9)

Funding (7 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)